|
contents | america | ||||
| Physical and Rehabilitation Congress Marvin A Sackner, M.D., Chief Executive Officer and Chairman, Board of Directors, Non-Invasive Monitoring Systems, Inc. announced NIMS will exhibit their new therapeutic acceleration platform, Exer-Rest, for the first time at the 16th European Congress of Physical and Rehabilitative Medicine to be held June 3-6, 2008 in Brugge, Belgium. 2A CE 0120, non-invasive, acceleration platform which has the configuration of a single or twin bed. Electrical actuation of this device produces whole body periodic acceleration (WBPA). Research publications indicate that it can serve as an alternative or complementary means for exercise in subjects who are incapable, injured or unwilling to exercise. Steven Mrha, Chief Operating Officer of NIMS will demonstrate this product at the exhibition space of the meeting. Mr. Mrha stated, "Dr. Jose A. Adams, Chief of Neonatology of Mt Sinai Medical Center of Greater Miami will present a paper co-authored by Dr. Sackner entitled 'Exer-Rest and Exercise: What's the Difference?' This paper will summarize the similarities and differences between moderate aerobic exercise and WBPA as administered with Exer-Rest. NIMS will exhibit Exer-Rest at Florida International Medical Expo from August 13-15, 2008 in Miami Beach, Florida and at Medica 2008 in Dusseldorf, Germany from November 19-22, 2008." NIMS supports a clinical trial to demonstrate the intended use of Exer-Rest for temporary relief of musculoskeletal pain associated with osteoarthritis of the lower extremities (hips and knees) in order to meet FDA approval for marketing in the United States. Exer-Rest can be marketed and sold in the common market and Canada. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including, but not limited to: risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. write your comments about the article :: © 2008 Exhibition News :: home page |